Probiotics Show Potential in Reducing Gastrointestinal Symptoms in Schizophrenia Patients, Study Finds

A recent clinical trial has highlighted the potential benefits of probiotic supplementation in managing gastrointestinal problems, particularly severe bowel difficulties, among patients with schizophrenia. While probiotic use did not significantly reduce core psychiatric symptoms of schizophrenia, it was found to be effective in reducing the likelihood of developing severe bowel issues, a common complication in this population.

The randomized, double-blind, placebo-controlled trial involved 65 outpatients with schizophrenia who were receiving antipsychotic treatment. Participants were given either a probiotic supplement containing Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12 or a placebo for 14 weeks. Psychiatric symptoms were regularly assessed, but no significant differences between the probiotic and placebo groups were observed in terms of psychotic symptom severity.

However, the probiotic group was significantly less likely to report severe difficulty with bowel movements during the trial—a notable finding given that up to 50% of schizophrenia patients suffer from constipation, often exacerbated by antipsychotic medications and lifestyle factors. The study suggests probiotic supplementation could offer a safe and well-tolerated strategy to improve gastrointestinal health in these patients.

Despite the lack of direct impact on psychiatric symptoms, the study supports further investigation into probiotics as an adjunct treatment, particularly for managing somatic symptoms like constipation that affect quality of life in schizophrenia. The researchers also highlight the need for clinical trials examining probiotic effects earlier in the course of schizophrenia.

Disclaimer: This information is based on a specific clinical study and should not be taken as medical advice. Patients should consult healthcare providers before starting any probiotic supplements, especially those with schizophrenia or other psychiatric conditions.

[References: Sheppard Pratt trial study summary 2014, systematic review 2019]